tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Optimistic Outlook for Vaxcyte’s Vaccines Drives Buy Rating
PremiumRatingsOptimistic Outlook for Vaxcyte’s Vaccines Drives Buy Rating
3M ago
Vaxcyte reports Q1 EPS ($1.04), consensus (98c)
Premium
The Fly
Vaxcyte reports Q1 EPS ($1.04), consensus (98c)
3M ago
Vaxcyte Appoints Dr. Olivier Brandicourt to Board
Premium
Company Announcements
Vaxcyte Appoints Dr. Olivier Brandicourt to Board
3M ago
Vaxcyte’s Promising Prospects: Buy Rating Reinforced by Positive Phase 2 Data and Strategic Expansion
PremiumRatingsVaxcyte’s Promising Prospects: Buy Rating Reinforced by Positive Phase 2 Data and Strategic Expansion
4M ago
Biotech Alert: Searches spiking for these stocks today
Premium
The Fly
Biotech Alert: Searches spiking for these stocks today
4M ago
Optimistic Buy Rating for Vaxcyte Amid Vaccine Development Challenges and Strategic Adjustments
Premium
Ratings
Optimistic Buy Rating for Vaxcyte Amid Vaccine Development Challenges and Strategic Adjustments
4M ago
Vaxcyte’s VAX-24: Promising Infant Vaccine Results Amidst Investor Concerns
PremiumRatingsVaxcyte’s VAX-24: Promising Infant Vaccine Results Amidst Investor Concerns
4M ago
Optimistic Outlook for Vaxcyte: Potential for Improved Vaccine Efficacy in Future Trials
Premium
Ratings
Optimistic Outlook for Vaxcyte: Potential for Improved Vaccine Efficacy in Future Trials
4M ago
Vaxcyte ‘narrow’ misses in Phase 2 likely to be ok in Phase 3, says Evercore ISI
Premium
The Fly
Vaxcyte ‘narrow’ misses in Phase 2 likely to be ok in Phase 3, says Evercore ISI
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100